Very early inflammatory bowel disease (IBD) is characterized by high levels of broad colon involvement and a reduced reaction rate to typical medical systems, including infliximab (IFX). After treatment with therapeutic medicines monitoring (TM) guided accelerated high-dose IFX therapy, we describe a case series of four baby IBD patients who achieve clinical and biological remisión. The IPX high-dose induction of up to 22 mg/kg was treated with all patients. In 3 of these individuals, high-dose accelerated IFX was applied after an increased induction of the normal dosage.

In order to establish and sustain remission, we believe that kids with IBD-induced infantiles would need a TDM-guided, high-dose induction and maintenance. In order to minimize underdosing and prevent incorrect interpretation of treatment failure, a personalized strategy is necessary in these individuals.